Insulin resistance is the quiet engine behind a lot of stubborn weight gain, and it’s one of the things GLP-1 drugs are genuinely good at addressing. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) both improve how your body responds to insulin, and research suggests part of that benefit goes beyond weight loss alone. Tirzepatide, with its dual mechanism, tends to move insulin-resistance markers the most. Here’s how these medications work on the underlying problem and how they compare.<\/p>\n
When cells stop responding well to insulin, the pancreas compensates by making more of it. Chronically high insulin promotes fat storage (especially around the abdomen), makes fat harder to lose, and drives up triglycerides and blood sugar. It’s a self-reinforcing loop: more abdominal fat worsens insulin resistance, which stores more fat.<\/p>\n
Insulin resistance sits upstream of prediabetes, type 2 diabetes, PCOS, and fatty liver disease, which is why improving it can ripple out to several conditions at once. Losing weight helps, but the mechanism of these drugs adds something beyond the weight itself.<\/p>\n
GLP-1 medications improve insulin sensitivity through several routes: weight loss reduces the fat that drives resistance, and the drugs also improve how the pancreas and other tissues handle glucose. Tirzepatide’s added GIP receptor activity appears to give it an edge on adipose tissue and insulin signaling.<\/p>\n